5269532025-10-012025-12-315269532025-04-012025-12-315269532025-10-012025-12-31in-capmkt:OtherExpenses1Member5269532025-10-012025-12-31in-capmkt:OtherExpenses2Member5269532025-04-012025-12-31in-capmkt:OtherExpenses1Member5269532025-04-012025-12-31in-capmkt:OtherExpenses2Member5269532025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15269532025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15269532025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss15269532025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares526953VENUSREMNOTLISTEDINE411B01019Venus Remedies LimitedMain BoardEquity2025-04-012026-03-312026-01-292026-01-19INRCroresQuarterlyThird quarterSingle segmentPharmaceuticle2026-01-2914:45:002026-01-2917:40:00Not applicablefalsefalseNo such defaults2025-10-012025-12-31UnauditedStandalone179950000024100000182360000093860000019000000-951000001994000000632000003704000001495500000328100000032810000082500000-36000007890000002492000000000249200000219000002711000001337000001018.6418.640018.6418.642025-04-012025-12-31UnauditedStandalone5097300000681000005165400000271700000060300000-100200000612300000018190000096290000044342000007312000000731200000184000000-1150000017250000005587000000000558700000631000006218000001337000001041.7941.790041.7941.79Selling, Manufacturing and Administrative Expenses328400000Research & Development expenses42000000Selling, Manufacturing and Administrative Expenses836500000Research & Development expenses126400000Items that will not be reclassified to Profit & Loss-300000-300000Items that will not be reclassified to Profit & Loss-2700000-270000000Items that may be reclassified to Profit & Loss2220000022200000Items that may be reclassified to Profit & Loss6580000065800000002190000063100000